Organisation paid for research Program year 2025 Source: CMS Open Payments

Sanford Research Center

Neither a doctor nor a teaching hospital

Research payments

$304,404

56 payments

Through program year 2025, Sanford Research Center is reported as receiving $304,404 in research payments, across 56 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $28,448 8
2024 Research $3,300 6
2023 Research $12,813 1
2022 Research $12,047 1
2021 Research $18,700 1
2020 Research $163,957 20
2019 Research $65,139 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Celgene Corporation $172,757 6 payments
  2. GlaxoSmithKline, LLC. $92,641 39 payments
  3. AstraZeneca UK Limited $18,700 1 payment
  4. Retrophin, Inc. $11,250 2 payments
  5. AbbVie, Inc. $3,515 5 payments
  6. E.R. Squibb & Sons, L.L.C. $3,045 1 payment
  7. Grifols Therapeutics LLC $2,496 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase Ib Motolimod Pre Surgerical Biomarker SCCHN (VTX-2337-HN-001) (BMS Study Number: CA075-P01) $125,431 1 payment
  2. RSV Ped-002 $55,969 8 payments
  3. Menb Rec 2Nd Gen-023 (V72_57) $31,122 22 payments
  4. A Phase 2 Study of RPC01-1063 in Patients with Multiple Sclerosis $24,860 2 payments
  5. A Phase 2 Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum Sensitive Relapsed Epithelial Ovarian Cancer, who have Previously Received PARP Inhibitor Maintenance Treatment $18,700 1 payment
  6. Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release $11,911 2 payments
  7. 021Igan17001 $11,250 2 payments
  8. Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release $8,500 1 payment
  9. A Randomized Phase 3 Double-Blinded Study Comparing the Efficacy and S $5,551 9 payments
  10. A Phase 3B, Multicenter, Open-Label Study to Evaluate the Immunological Response To, and the Safety Of, Three Parenterally Administered Vaccines in Subjects With Relapsing Remitting Multiple Sclerosis Who Receive Oral Ozanimod, Non-Pegylated Interferon-, Or No Disease Modifying Therapy $5,100 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Other $11,250 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record